Liposome-encapsulated hemoglobin (LEH) is an erythrocyte substitute that is a potential resuscitative fluid for the in vivo delivery of oxygen. We have noninvasively imaged radiolabeled LEH in vivo with technetium-99m (""Tc) to study the biodistribution in an anesthetized rabbit. Rabbits (2.5 kg, n = 8) were infused with 30 ml of LEH (200 mg of phospholipid, 2.5 g of hemoglobin per kg of body weight) and imaged with a y camera continuously for 2 hr. At 20 hr postinfusion, the animals were inaged again and sacrificed; the organs were weighed and their radioactivity was determined for autopsy organ distribution. Organ uptake from the images was corrected for organ-associated blood pool, which was determined by infusion of "9mTc-labeled rabbit erythrocytes.
to study the biodistribution in an anesthetized rabbit. Rabbits (2.5 kg, n = 8) were infused with 30 ml of LEH (200 mg of phospholipid, 2.5 g of hemoglobin per kg of body weight) and imaged with a y camera continuously for 2 hr. At 20 hr postinfusion, the animals were inaged again and sacrificed; the organs were weighed and their radioactivity was determined for autopsy organ distribution. Organ uptake from the images was corrected for organ-associated blood pool, which was determined by infusion of "9mTc-labeled rabbit erythrocytes.
Blood pool and decay-corrected biodistribuion data reveal the kinetics of LEH distribution, with an initial rapid uptake by the liver, 8% at 30 min and 15% at 2 hr. The spleen accumulates less LEH initially, 3% at 30 min and 7% at 2 hr, with an apparent linear uptake of LEH over this time period. Image biodistribution data was also validated at 20 hr by tissue sampling. At 20 hr postinfusion, autopsy biodistribution data reveals approximately 42.6% of the total counts remaining in the blood, 15 .4% in the liver, 18 .1% in spleen, 3.2% in the lungs, 2.4% in muscle, 1.6% in urine, and trace levels in the kidney, brain, and heart (<1%). There is no evidence of hemoglobin release from LEH or kidney dysfunction (normal creatinine and blood urea nitrogen) at any time over the course of the study.
The need for blood in trauma care, its uncertain supply, and the risk of transmittable antigens associated with using the current blood reserves has fueled the search for a substitute oxygen-carrying resuscitative fluid. One effort in the search for an adequate substitute has been to use modified stromafree hemoglobin because infusion of the hemoglobin tetramer has been demonstrated to cause a variety of toxic responses in vivo (1) . Modifications such as chemical cross-linking and polymerization of the tetramer have improved some of these deleterious properties (2) . Although modified hemoglobin solutions 'may show promise, the remaining problems associated with stroma-free hemoglobin preparations are potential nephrotoxicity and antigenicity (3) . The development of recombinant technology to produce hemoglobin may alleviate the problems of finding adequate sources and potentially tainted blood supplies, and recent advances in this direction have been reported (4) .
One solution to the problems associated with hemoglobinbased blood substitutes regardless of the source is the encapsulation of hemoglobin within a liposome. This has the potential to reduce the toxicity of hemoglobin whether in the tetrameric, cross-linked, polymerized, or recombinant forms as liposomes have been proven to reduce the toxicity of a number of bioactive agents (5-7). In addition, the encapsulation of active agents into liposomes increases the circulation persistence of pharmacological materials (8) . Sufficient circulation persistence is essential for an oxygen-carrying material in applications where oxygen delivery may be required for prolonged periods.
Some of the desired properties of an encapsulated oxygencarrying material have been realized in the development of liposome-encapsulated hemoglobin (LEH) (for a recent review, see ref. 9). Efficacy of this material (as determined by in vivo oxygen-carrying capacity) has been demonstrated in total isovolemic exchange transfusions in anesthetized rats (10) (11) (12) . Hemodynamic consequences of small doses of LEH ('10 mg/kg of body weight) have been studied in a normovolemic conscious rat model (13) (14) (15) . These studies revealed a variety of transient effects (thrombocytopenia, leukocytosis, rise in blood pressure, and drop in cardiac output), which were alleviated by the substitution of a synthetic hydrogenated phosphatidylcholine for natural soy lecithin (which contained lysolecithin contamination) and by a synthetic platelet-activating factor antagonist (13, 14) . Circulation persistence of LEH has been measured in rodents and is '15 hr at moderate doses (10, 15, 16) . Other important milestones in the development of LEH have been the sterile large-scale production and long-term shelf-life of LEH in the freezedried state (17) (18) (19) . Although recent studies have focused on in vivo effects of LEH, little is known regarding the biodistribution of LEH and the interaction with'the reticuloendothelial system (RES).
The large body of evidence regarding liposome removal from circulation indicates that the RES is largely responsible for liposome removal (20) (21) (22) (23) (24) (25) (26) . Modifications to liposomes such as lipid composition (e.g., cholesterol, degree of fatty acid saturation, and chain length), surface charge, and size all influence the physiological traffic pattern of liposomes (22) . The use ofradiolabels has proven quite useful in following the fate of liposomes in vivo and as diagnostic tools in nuclear medicine (24) (25) (26) (27) (28) . The methods employed to label liposomes include entrapment of the radiolabel in the aqueous compartment, attachment of the label to lipid components prior to liposome formation, and the addition of label after their manufacture.
We have previously reported the use of hexamethylpropylene amine oxime (HMPAO), a lipophilic transporter of 9'Tc, to radiolabel LEH with 199Tc (29 (29) .
Animal Protocol. Male rabbits (2-2.5 kg, n = 8) were anesthetized intramuscularly using a 5:1 (vol/vol) mixture of ketamine (50 mg/kg) and xylazine (10 mg/kg) 30 After 2 hr of continuous imaging, the catheters were removed, and the rabbits were allowed to recover from anesthesia and were housed in cages with food and water ad libitum. Urine from housed animals was collected for determination of the amount of radioactivity and biodistribution. At 20 hr postinfusion, rabbits were anesthetized, and a static image and blood samples of the rabbit was taken. Rabbits were then sacrificed, and the major organs and known volumes of blood and urine were removed for weighing and determining the amount of radioactivity. Approximately 2-to 3-g samples of each organ were weighed and assayed on a multichannel analyzer (Canberra, Meriden, CT) to determine counts per g of tissue and total organ activity. Organ and fluid counts too high for detection at the time of sacrifice were stored until decay allowed for accurate determination.
Blood Pool Correction. Blood pool correction was performed on imaged biodistribution data by first calculating blood pool contribution in various organs by imaging 'mTclabeled rabbit erythrocytes. Heparinized blood (6.0 ml) was drawn from 2.5-kg New Zealand White rabbits (n = 3) and added to a Cadema RBC kit (Middleton, NY). The blood and freeze-dried material were reconstituted by gentle agitation for 5 min, after which time 1.0 ml of 4.4% EDTA was added.
The tube was inverted and centrifuged at 1300 x g for 5 min. While the tube was inverted, 2.0 ml of packed erythrocytes were removed and transferred to a sterile vial containing 2.0 ml of saline and 4 mCi of sodium [9'Tc] pertechnetate. The sample was mixed gently and incubated for 10 min at room temperature before injection into the ear vein. A 0.1-ml aliquot (0.2 mCi) was included in the field of view as a standard reference dose. After adequate equilibration of the injected erythrocytes (usually within S min postinfusion), a 1-min image was acquired and analyzed. Regions of interest were drawn around selected organs. Blood pool contribution of each organ was measured as follows: (counts in organ x attenuation correction factor)/(counts in 0.1-ml reference dose x 20) (the total dose injected was 2.0 ml). Labeling efficiencies using this procedure were >95%, and there was minimal loss of free label in the early images. Table 1 shows the blood pool correction for the heart, lung, liver, spleen, and left kidney. The percentage of blood pool counts subtracted from each organ is based on the percentage of counts in a particular organ as determined from Table 1 multiplied by the estimated percentage of total LEH dose remaining in the entire blood pool. The estimated percentage of total LEH dose given that remains in the blood pool at any one time is based on counts taken from the extracted capillary blood samples taken over the 2 hr.
Image Analysis. Camera sensitivity was determined over the millicurie range of the injected dose (3-7 mCi) and was found to be linear. An attenuation correction factor was also empirically derived and used for final calculations of imaged biodistributions. Image analysis for LEH organ biodistribution was performed after the images were transferred to a nuclear medicine analysis workstation (Pinnacle computer, Medasys). Whole images were corrected for decay and the attenuation factor using software written for the image workstation. Regions of interest were drawn around the heart, lungs, liver, spleen, kidney, bladder, and the LEH standard for each rabbit.
Blood clearance and biodistribution studies were also performed with free 99"Tc-HMPAO for comparison with 99ITc-LEH. The HMPAO kit was hydrated with 5 ml of saline containing 5 mCi of [pTc]pertechnetate. After S min at room temperature, the 5-ml sample was injected over 30 sec into the ear vein. At 2, 5, 10, 30, 60, and 120 min postinjection and at 20 hr just prior to sacrifice, a 0.1-ml sample of blood was withdrawn. A 0.1-ml aliquot of 99mTc-HMPAO was used as reference for imaging and tissue studies. The percentage of the total injected dose remaining 
RESULTS
The location of 99"Tc in labeled LEH following the labeling procedure is an important determinant of the observed biodistribution. An organic extraction procedure used to separate LEH components revealed that 9.5% ± 1.0% of the activity remains in the organic phase, 22.1% ± 0.7% is found in the aqueous phase, and 67.5% ± 2.5% is observed associated with the hemoglobin fraction. This may indicate that the label may have a higher affinity for the hemoglobin than for HMPAO once it is carried across the liposome bilayer.
Previous reports indicate that the (8 chain of hemoglobin may be a potential 9'Tc binding site (31, 32) . The conversion of lipophilic HMPAO to a intravesicular hydrophilic form may also be aided by the presence of encapsulated glutathione as this reductant is thought to play a role in trapping 99,Tc-HMPAO once it has crossed the blood-brain barrier for use in brain imaging (33) . Alternatively, the 991Tc-HMPAO complex may precipitate with the hemoglobin (or glutathione) in the extraction protocol, and the identification of 9'Tc with the hemoglobin fraction may not indicate a direct protein association.
A typical example of the image acquired at the end of the infusion (after =30 min) is shown in Fig. 1 . The majority of the intensity visualized at this time is due to the presence of LEH in blood vessels and organ-associated blood pools. It is important to note that little intensity is visualized in the bladder, stomach, or thyroid at this time point, indicating that the 9I1Tc does not readily dissociate from LEH. Further evidence of the stability of 99mTc in vivo is seen in Fig. 2A , which shows the y emission profile from a single blood-drawn capillary tube that was centrifuged. The imaged intensity has a narrow peak where the LEH pellet is found. This is also observed in the capillary blood samples drawn at 15-min intervals following infusion of LEH (Fig. 2B ). These images show activity only in the LEH fraction above the erythrocyte pellet. No activity was observed from images of capillary tubes in the plasma or erythrocyte fraction at any time point examined.
The disappearance of activity from the LEH fraction in the capillary blood samples has been used to generate a clearance profile based on the percent of injected dose in the total A*- estimated blood level (Fig. 3) . The clearance profile suggests that LEH is removed rapidly over the first 2 hr (20% is removed at 30 min). A slower secondary removal phase is seen between 4 and 20 hr, with -45% remaining in the blood pool at 20 hr. In contrast, the clearance of 99mTc-HMPAO is quite rapid with only 10%o remaining in the blood pool 2 min after the infusion. This is in agreement with previous studies of 991Tc-HMPAO clearance, which show little circulation persistence and rapid metabolic conversion of HMPAO (34) .
The images collected over the 2 hr following LEH infusion show the slow disappearance of LEH from the blood pool with increasing organ uptake. Fig. 4A shows the percent of injected dose in each organ region from the collected images 2 hr postinfusion (not corrected for organ blood pool). These data indicate that the liver accumulates the greatest quantity of LEH, with intensity that increased rapidly (almost 20o at 15 min) and that remained at high levels ('30% of total counts) over the 2-hr dynamic image acquisition. The counts in the spleen increase linearly over 2 hr to almost 7%, with similar counts in the heart. The remaining imaged organ regions (lung, kidney, and bladder) show little activity (<2%) even at 2 hr postinfusion. Fig. 4B shows the blood pool corrected biodistribution over the 2-hr period and reveals that the liver and spleen are the only organs that show measurable activity. The lung shows only trace activity over this time period.
At 20 hr, the validity of the imaged biodistribution was examined by tissue sampling. Table 2 compares the imaged (both corrected and background subtracted) and autopsy biodistribution at 20 hr for both 9'9Tc-LEH and 'Tc-HMPAO. The autopsy biodistribution at 20 hr reveals that the blood pool still has the greatest 99"Tc-LEH-associated activity with 42.6% ± 6.0% remaining in circulation. The organ with the most accumulation of LEH is the spleen with 18.1% ± 3.3%, followed by the liver with 15.4% ± 2.1%. It is important to note the validity of the blood pool corrected image data by comparing the autopsy biodistribution values for these organs (in which the organ-associated blood pool is washed out) to the blood pool corrected image data. The blood pool corrected percent of injected dose/imaged organ region is 14.6% ± 2.8% for the liver, compared to the autopsy value of 15.4% ± 2.1%. For the spleen, the blood pool corrected percent of injected dose/imaged organ region is 18.0%o ± 4.5%, whereas the autopsy biodistribution is 18.1% + 3.3%. It may be that the blood pool correction for those organs that have very little associated accumulation of LEH such as the heart, lungs, and kidneys is more sensitive to correction and thus accounts for the reported negative values for the blood pool corrected image data for the heart and kidney. This is supported by the autopsy biodistribution at 20 hr, which shows very little accumulation in the heart and kidney with only minimal accumulation (3% or less) in the lungs, muscle, and urine. The total activity accounted for in the autopsy was 84.2%. The remaining activity could be in sites of LEH accumulation not measured such as the bone marrow, which is an active site of RES activity. 
DISCUSSION
One of the essential requirements for an effective oxygencarrying resuscitative fluid is the ability to carry oxygen for prolonged periods in scenarios where an oxygen deficit may be encountered (e.g., bleeding injury or organ perfusion). The biodistribution data presented here indicate that there is significant retention of LEH (43%) in circulation at 20 hr, which is significantly longer than most modified hemoglobin preparations (2, 3) . The image biodistribution of LEH 2 hr after infusion reveals that LEH accumulates in the liver and spleen. The kinetics over this period of LEH uptake show that the liver accumulates LEH rapidly, with a slower uptake by the spleen. Additional LEH is removed by the spleen over 20 hr to result in almost equivalent removal of LEH in liver and spleen at 20 hr. These results indicate that LEH accumulates in RES organs, and at the given dose, the RES may become saturated over the course ofthe rapid removal phase. The blood clearance profile of 99mTc-LEH also supports two phases of LEH removal, with a fast removal over the first 2 hr and slower disappearance out to 20 hr. It is unclear, however, whether LEH localized in the organs as observed by image biodistribution is located intracellularly (by phagocytosis) or is sequestered by the organ without active uptake and metabolism by cells of the RES.
The fate of the encapsulated hemoglobin over the course of this experiment apparently tracks the distribution of the liposomes. There is no evidence of leakage of intravesicular free hemoglobin from the aqueous compartment of LEH. There is no free hemoglobin or label (99'Tc) observed in the plasma fraction of blood-drawn capillary tubes over the course of the experiment. This would also be evidenced by 99mTc activity in the bile (intestine), kidney, or bladder, which was not observed, in contrast to the considerable activity of these organs in animals given '9Tc-HMPAO. Urine removed from the bladder upon autopsy did show a small amount of label (2%), which may be due to some dissociation of label from LEH or, alternatively, LEH metabolism. There was negligible 99'Tc-LEH imaged in the kidney, and no measurable hemoglobin was found in the urine. This is an important finding for a hemoglobin-based oxygen-carrying fluid because of the long history of accumulation of hemoglobin in the kidney and associated nephrotoxicity. The measurement of LEH uptake into the RES by imaging intensity in organ regions ofinterest is somewhat complicated by blood pool contributions. Overall, our methods of blood pool correction have resulted in accurate estimations oforgan uptake from acquired images, especially when compared to tissue sampling at 20 hr.
The in vivo stability of9Tc-HMPAO could also affect the observed biodistribution. Previous reports of the stability of 9Tc-HMPAO in saline show that there is rapid loss of radiochemical purity (60%6) over the course of 2 hr (35) . These studies showed that the in vivo administration of 9'Tc-HMPAO resulted in rapid clearance of the label from the blood pool, with metabolism and transfer of the label to other blood elements. Previous biodistribution studies show accumulation of free 1'Tc-HMPAO in the kidney, bile, and intestine (28, 35) . Our results confirm the rapid clearance of 9'9Tc-HMPAO from the blood pool with significant accumulation in the urine. In contrast, the in vivo stability of 99mTc-LEH shows long retention in the blood pool (45% at 20 hours) and no transfer of the label to other blood elements, as evidenced by sampling peripheral blood from animals given 99mTc-LEH. This suggests that the encapsulation ofthe label within the liposome retards the metabolism of 9'9Tc-HMPAO while LEH resides in the RES. The efficient encapsulation of the label in LEH may involve the reduction of the radiolabel by the coencapsulated glutathione. This labeled liposome system may prove to be a superior technetium label for clinical imaging diagnostics.
The present report offers promising results toward the further development of this oxygen-carrying resuscitative fluid. The distribution and uptake of the dose of LEH used in this study results in dissemination of LEH to the RES: principally the liver and spleen with minimal involvement of the kidney. Blood chemistries taken over the course of the experiment indicate that there are transient increases in SGOT and SGPI and no increase in bilirubin or serum creatinine.
This correlates with the observed uptake in the liver with little distribution to the kidney. The observed half-life of '18 hr may be related to the two rates of LEH accumulation in organs of the RES and could indicate that the liver is saturated at the given dose. The significant involvement of the RES in removal of LEH also suggests that further experiments into the metabolic fate of LEH after handling by the RES are warranted. It may also be important to consider the effect of secondary immune challenge after LEH infusion, repeated LEH dosing, and the oxygen-carrying capacity of LEH in scenarios appropriate to its eventual application.
